Literature DB >> 17973322

Skeletal Langerhans cell histiocytosis in children: permanent consequences and health-related quality of life in long-term survivors.

Loretta M S Lau1, Kyra Stuurman, Sheila Weitzman.   

Abstract

BACKGROUND: The skeleton is the most frequently involved organ in Langerhans cell histiocytosis (LCH) in children, and bone LCH generally has an excellent long-term survival. Although permanent consequences (PC) are described in half of the survivors thus raising concerns for quality of life (QOL), the impact on quality of life has not been formally studied.
METHODS: A retrospective review was performed on 124 LCH patients with skeletal involvement, followed by prospective evaluation of PC and health-related QOL using age-appropriate validated study tools (PedsQL or SF-36).
RESULTS: Of the 116 survivors, PC were found in 34 (29%) patients, of whom 8 had more than 1 PC. PC were significantly more frequent in multi-system (M-S) than in single system (S-S) LCH (73% vs. 17%; P < 0.0001). While diabetes insipidus (65%) was the most common PC in M-S LCH, cosmetic and orthopedic problems made up the majority of PC in S-S LCH. The median follow-up time was 8.5 years. 27 patients completed the PedsQL survey and 22 the SF-36 survey. The QOL scores for LCH patients were not significantly different from healthy children in the PedsQL survey and from young adults in the SF-36 survey. In addition, the QOL scores were very similar between patients with and without PC and between patients with M-S and S-S LCH.
CONCLUSIONS: Children with M-S LCH had a significantly higher risk of developing PC. Skeletal LCH did not adversely affect the quality of life of survivors, including those with PC who appeared to adapt to their disabilities and medical problems. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 17973322     DOI: 10.1002/pbc.21322

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  9 in total

1.  Social/economic costs and health-related quality of life in patients with histiocytosis in Europe.

Authors:  Georgi Iskrov; Itziar Astigarraga; Rumen Stefanov; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Arrigo Schieppati; Domenica Taruscio; Márta Péntek; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-04

2.  Langerhans cell histiocytosis: 37 cases in a single brazilian institution.

Authors:  Luciana Terra Babeto; Benigna Maria de Oliveira; Lúcia Porto Fonseca de Castro; Márcia Kanadani Campos; Maria Thereza Macedo Valadares; Marcos Borato Viana
Journal:  Rev Bras Hematol Hemoter       Date:  2011

3.  Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis.

Authors:  Liliana Montella; Carmela Merola; Geraldina Merola; Luigi Petillo; Giovannella Palmieri
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

4.  Percutaneous CT-guided corticosteroid injection for the treatment of osseous Langerhans cell histocytosis: a three institution retrospective analysis.

Authors:  Connie Y Chang; Julio Brandao Guimares; Gabby Joseph; Marcelo de Toledo Petrilli; Santiago Lozano-Calderon; Miriam A Bredella; Thomas M Link
Journal:  Skeletal Radiol       Date:  2021-10-04       Impact factor: 2.199

Review 5.  Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies.

Authors:  Caroline Hutter; Milen Minkov
Journal:  Immunotargets Ther       Date:  2016-10-12

6.  Langerhans cell histiocytosis: Current concepts in dentistry and case report.

Authors:  Efraín Ramos-Gutiérrez; Francisco Alejo-González; Socorro Ruiz-Rodríguez; José-Arturo Garrocho-Rangel; Amaury Pozos-Guillén
Journal:  J Clin Exp Dent       Date:  2016-02-01

Review 7.  Langerhans cell histiocytosis in children - a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment.

Authors:  Michalina Jezierska; Joanna Stefanowicz; Grzegorz Romanowicz; Wojciech Kosiak; Magdalena Lange
Journal:  Postepy Dermatol Alergol       Date:  2018-02-20       Impact factor: 1.837

8.  Psychological features of adult patients with langerhans cell histiocytosis.

Authors:  Emmanuelle Bugnet; Nishant Gupta; Gwenaël Lorillon; Sayena Arbabzadeh-Bouchez; Cédric Lemogne; Sylvie Chevret; Abdellatif Tazi
Journal:  PLoS One       Date:  2021-02-12       Impact factor: 3.240

9.  Treatment and Outcomes of Unifocal and Multifocal Osseous Pelvic Langerhans Cell Histiocytosis Lesions in a Pediatric Population.

Authors:  Parker Mitchell; Ekene U Ezeokoli; Neritan Borici; Eva Schleh; Nicole Montgomery
Journal:  Cureus       Date:  2022-08-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.